铁过载患者的血糖调节异常:与MRI测量的胰腺和肝脏铁及脂肪含量是否相关?
回顾性评估105例铁过载患者的胰腺和肝脏R2*、脂肪分数(FF)、肝铁浓度(LIC)及血糖代谢,发现血糖调节异常组与血糖正常组的胰腺R2*、肝脏R2*和FF无显著差异,但胰腺FF显著更高(23.5% vs 16.7%,p=0.011);胰腺FF而非胰腺R2*与血糖调节异常相关,胰腺FF预测血糖调节异常的AUC为0.666。
要点
- 铁过载患者中胰腺FF与血糖调节异常相关,而胰腺R2*无显著相关。
- 胰腺FF预测血糖调节异常的AUC为0.666,阈值26.2%时敏感度45%、特异度80%。
- MRI同时测量胰腺铁和脂肪可避免两者在定量分析中的相互混杂。
核心结论
- 在铁过载患者中,胰腺FF而非胰腺R2*与血糖调节异常相关。
- 既往研究报告胰腺R2*与血糖调节异常相关,可能源于MRI技术或分析不充分,未同时测量脂肪和铁以规避混杂效应。
研究设计与样本
- 回顾性评估105例铁过载患者,采用多回波梯度回波R2*技术测量胰腺和肝脏R2*、FF、LIC,并评估血糖代谢。
关键影像表现/征象
- 血糖调节异常组与血糖正常组的胰腺R2*、肝脏R2*和FF无显著差异(p分别为0.435、0.674、0.976)。
- 血糖调节异常组的胰腺FF显著高于血糖正常组(23.5% vs 16.7%,p=0.011)。
- 胰腺R2*与胰腺FF弱相关(r=0.388,p<0.001),与肝脏R2*弱相关(r=0.201,p=0.033),与肝脏FF无相关(r=-0.013,p=0.892),与LIC分类无相关(p=0.493)。
诊断标准与关键数值
- 胰腺FF预测血糖调节异常的AUC为0.666,胰腺R2*的AUC为0.571。
- 胰腺FF阈值26.2%预测血糖调节异常的敏感度为45%、特异度为80%。
临床应用与阅片要点
- 在铁过载患者的MRI定量分析中,应同时测量胰腺铁(R2*)和脂肪(FF),以避免两者相互混杂。
- 胰腺FF可能用于预测铁过载状态下的血糖调节异常。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: The aim was to investigate the relationship between pancreatic and hepatic iron and fat to glucose metabolism in patients with iron overload and address conflicting results in literature as regards the relationship between pancreas iron and glucose dysregulation.
METHODS: We retrospectively evaluated pancreatic and hepatic R2*, fat fraction (FF), liver iron concentration (LIC), and glucose metabolism in 105 patients with iron overload obtained with a multi-echo gradient echo R2* technique and assessed the correlation between pancreatic R2* and FF to glucose dysregulation.
RESULTS: There were no significant differences in pancreatic R2*, liver R2*, and FF in patients with iron overload and glucose dysregulation compared to those with normoglycemia (p = 0.435, p = 0.674, and p = 0.976), whereas pancreatic FF was significantly higher, 23.5% vs 16.7% respectively (p = 0.011). Pancreatic FF and R2* demonstrated an area under the curve of 0.666 and 0.571 for discriminating glucose dysregulation. Pancreatic FF of 26.2% yielded specificity and sensitivity of 80% and 45% for prediction of glucose dysregulation. Pancreatic R2* weakly correlated with pancreatic FF, r = 0.388 (p < 0.001), and liver R2*, r = 0.201 (p = 0.033), and showed no correlation with hepatic FF r = -0.013 (p = 0.892) or LIC categories (p = 0.493).
CONCLUSION: Pancreatic FF but not pancreatic R2* was associated with glucose dysregulation in patients with iron overload. Prior studies reporting correlation of pancreatic R2* to glucose dysregulation likely relate from inadequate MRI technique or analysis employed, which unlike our study did not perform simultaneous measurements of fat and iron essential to avoid their confounding effects during quantitative analysis.
KEY POINTS: • Pancreatic fat fraction, unlike iron, is associated with glucose dysregulation in iron overload. • Simultaneous measurement of pancreatic iron and fat content with MRI is essential to avoid confounding effects of one another during quantitative analysis. • Pancreatic fat fraction could be utilized to predict glucose dysregulation in iron overload states.
引用
- Shur J, Kannengiesser SAR, Menezes R, et al. Glucose dysregulation in patients with iron overload: is there a relationship with quantitative pancreas and liver iron and fat content measured by MRI? Eur Radiol. 2019. PMID: 31712958. doi:10.1007/s00330-019-06487-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。